Prophylaxis for Contacts of an Infant with Bacterial Meningitis

Immediate Action Required

Household contacts of an infant with bacterial meningitis require immediate antibiotic prophylaxis within 24 hours, with the specific regimen depending on the causative organism, according to the American Academy of Pediatrics 1, 2
Public health authorities should be notified immediately, and prophylaxis decisions should be deferred to the Consultant in Communicable Disease Control or public health team, as recommended by the Centers for Disease Control and Prevention 3
Prophylaxis must be administered within 24 hours of case identification for maximum effectiveness, as stated by the World Health Organization 2

Household members, intimate kissing contacts, and anyone directly exposed to the patient's oral secretions within 7 days before illness onset should receive prophylaxis, according to the Centers for Disease Control and Prevention 3, 4, 1
Close contacts are defined as those living or sleeping in the same household, pupils in the same dormitory, boyfriends/girlfriends, and university students sharing a kitchen, as defined by the European Centre for Disease Prevention and Control 4
Classmates and nursery contacts do not require prophylaxis unless they meet close contact criteria, as stated by the American Academy of Pediatrics 4

Adults and children over 16 years should receive 500 mg oral single dose of ciprofloxacin, as recommended by the Centers for Disease Control and Prevention 3, 1, 2
Children 5-12 years should receive 250 mg oral single dose of ciprofloxacin, as stated by the World Health Organization 3
Children under 5 years should receive 30 mg/kg (maximum 125 mg) oral single dose of ciprofloxacin, as recommended by the American Academy of Pediatrics 3

Adults and children over 12 years should receive 600 mg orally twice daily for 2 days of rifampin, as stated by the Centers for Disease Control and Prevention 3, 1
Children 1-12 years should receive 10 mg/kg orally twice daily for 2 days of rifampin, as recommended by the World Health Organization 3, 1
Infants under 12 months should receive 5 mg/kg orally twice daily for 2 days of rifampin, as stated by the American Academy of Pediatrics 3, 1

The risk of meningococcal disease increases 400-800 fold in close contacts, with secondary attack rates of 2-4 per 1000 population, as reported by the Centers for Disease Control and Prevention 2
An increased risk persists for 6 months after exposure, even with prophylaxis, as stated by the World Health Organization 3, 2
Contacts should be monitored for symptoms for at least 10 days after exposure, as recommended by the American Academy of Pediatrics 1, 2

Meningococcal C vaccine should be offered to unvaccinated contacts of non-B serogroup cases, as recommended by the Centers for Disease Control and Prevention 3
Serogroup B vaccination should be offered to all household contacts if 2 or more cases of serogroup B disease occur in the same family, as stated by the World Health Organization 3

Prophylaxis is required only when the household contains an at-risk individual, such as a child under 10 years or an immunosuppressed person of any age, as recommended by the American Academy of Pediatrics 2
All household contacts and the index case should receive rifampin if an at-risk individual is present, as stated by the Centers for Disease Control and Prevention 2

Adults should receive 600 mg orally once daily for 4 days of rifampin, as recommended by the World Health Organization 2
Children 1 month-12 years should receive 20 mg/kg (maximum 600 mg) orally once daily for 4 days of rifampin, as stated by the American Academy of Pediatrics 2
Infants under 1 month should receive 10 mg/kg orally once daily for 4 days of rifampin, as recommended by the Centers for Disease Control and Prevention 2

Close contacts of pneumococcal meningitis do not require antibiotic prophylaxis, as they are not at increased risk, as stated by the American Academy of Pediatrics 2
The index case should receive pneumococcal vaccination after recovery to reduce recurrence risk, as recommended by the Centers for Disease Control and Prevention 2, 5